Vincent LeVien resigned as Director at Celularity Inc.
“Effective June 26, 2026, Vincent LeVien resigned as a member of the Company’s Board of Directors.”
Celularity Inc — fact timeline
Source-grounded facts extracted from Celularity Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Rick Gonzalez was appointed as Chief Commercial Officer at Celularity Inc.
“On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity.”
Celularity Inc entered into Settlement Agreement with Helena Global Investment Opportunities 1 Ltd. (effective 2026-05-21).
“On May 21, 2026, the Company entered into a Settlement Agreement with Helena in connection with certain existing transaction documents between the Company and Helena, including the Securities Purchase Agreement, dated as of October 24, 2025, and related instruments.”
Celularity Inc incurred loan of $500,000 immediately and (ii) five (5) consecutive monthly payments of $100,000 with Helena Global Investment Opportunities 1 Ltd..
“In connection with the settlement, Helena surrendered its shares of Series A Convertible Preferred Stock, and the Company agreed to pay Helena (i) pay $500,000 immediately and (ii) five (5) consecutive monthly payments of $100,000, assign certain rights under a $2,500,000 promissory note, and enter into related settlement documents, including an amendment to the existing security agreement.”
Celularity Inc reported a default on convertible notes with Helena Global Investment Opportunities 1 Ltd. at 15% per annum.
“On April 17, 2026, Helena delivered to the Company a notice of event of default (the “Default Notice”) under the Helena Note.”
Celularity Inc incurred convertible notes of $1,970,502.58 with Helena Global Investment Opportunities 1 Ltd. at 18.0% per annum maturing October 16, 2026.
“for a Convertible Promissory Note in the original principal amount of $1,970,502.58 (the “Helena Note”). The Helena Note bears interest at a rate of 18.0% per annum and matures on October 16, 2026”
Celularity Inc amended Amendment No. 1 with NexGel, Inc. valued at $13.3 million (effective 2026-04-17).
“On April 17, 2026, Celularity Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Asset Purchase and Exclusive License Agreement, dated as of March 6, 2026 (the “Original Agreement” and, as amended, the “Agreement”), with NexGel, Inc. (“NexGel”). Among other things, the Amendment provides that: (i) the aggregate consideration payable to the Company under the Agreement is $13.3 million, consisting of an upfront cash payment of $8.3 million on the transaction commencement date and a convertible promissory note in the original principal amount of $5.0 million with an 18-month term”
Celularity Inc entered into Asset Purchase and Exclusive License Agreement with NexGel, Inc. valued at up to $35.0 million in cash (effective 2026-03-06).
“On March 6, 2026, Celularity Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase and Exclusive License Agreement (the “Agreement”) with NexGel, Inc., a Delaware corporation (the “Licensee”), whereby the Company granted to the Licensee an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs as more fully described in the Agreement and the Company agreed to sell to the Licensee assets related to the portfolio (collectively, the “Business”). Consideration for the Business will consist of up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million upfront payment and (ii) an additional $20.0 million in potential milestone payments based on net sales targets related to the Business.”
Celularity Inc entered into Convertible Note Purchase Agreement with accredited investor valued at Senior secured convertible promissory note in the principal amount of $3,000,000 and a warrant to pu (effective 2025-12-19).
“On the Effective Date, the Company also entered into a Convertible Note Purchase Agreement (the “Convertible Note Securities Purchase Agreement”), with the Investor pursuant to which the Company issued the Investor a senior secured convertible promissory note in the principal amount of $3,000,000 (the “Convertible Note” and together with the Senior Note, the “Notes”) and a warrant to purchase up to 1,258,740 shares of the Company’s Class A common stock (the “Convertible Note Warrant”).”
Celularity Inc entered into Senior Securities Purchase Agreement with accredited investor valued at Senior Secured Non-Convertible Promissory Note in the principal amount of $7,000,000 and a warrant t (effective 2025-12-19).
“On December 19, 2025 (the “Effective Date”), Celularity Inc. (the “Company”) entered into a series of agreements relating to (i) a senior secured note financing (the “Senior Secured Note Financing”) and (ii) a convertible note financing (the “Convertible Note Financing” and together with the Senior Secured Note Financing, the “Financings”) with an accredited investor (the “Investor”).”
Celularity Inc issued 1,258,740 shares of the Company’s Class A common stock of warrant to accredited investor.
“the Company issued the Investor a senior secured convertible promissory note in the principal amount of $3,000,000 (the “Convertible Note” and together with the Senior Note, the “Notes”) and a warrant to purchase up to 1,258,740 shares of the Company’s Class A common stock (the “Convertible Note Warrant”)”
Celularity Inc issued convertible note to accredited investor for principal amount of $3,000,000.
“the Company issued the Investor a senior secured convertible promissory note in the principal amount of $3,000,000 (the “Convertible Note” and together with the Senior Note, the “Notes”)”
Celularity Inc issued 2,448,917 shares of the Company's Class A common stock of warrant to accredited investor.
“the Company issued the Investor a Senior Secured Non-Convertible Promissory Note in the principal amount of $7,000,000 (the “Senior Note”) and a warrant to purchase up to 2,448,917 shares of the Company’s Class A common stock (the “Senior Note Warrant”)”
Celularity Inc issued preferred stock to an institutional investor for 90% of the stated value.
“with the Series A Preferred Stock, the “Securities”). Under the Purchase Agreement, the Series A Preferred Stock will be issued and sold at a purchase price equal to 90% of the stated value, with each Preferred Share having a stated value of $1.111111 per share, and the Warrants will be issued for no additional consideration. Each Warrant will”
Celularity Inc: Filed Certificate of Designation for Series A Convertible Preferred Stock, establishing rights and preferences for 6,000,000 shares of Series A Preferred Stock (effective 2025-10-24).
“On October 24, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, designating 6,000,000 shares of Series A Preferred Stock, out of the Company’s authorized preferred stock.”
Celularity Inc incurred loan of $6,812,230 with an investor at 2% per annum maturing March 21, 2026.
“On July 21, 2025, Celularity Inc. (the “Company”) issued a promissory note in the aggregate principal amount of $6,812,230 (the “Note”) to an investor (the “Investor”).”
Joseph DosSantos was appointed as interim CFO at Celularity Inc.
“appointed Joseph DosSantos, its current Senior Vice President Finance, as the Company's interim CFO while the Company conducts a search for a new CFO.”
David Beers was terminated as Chief Financial Officer at Celularity Inc.
“terminated the employment of David Beers, its Chief Financial Officer without cause”
Vincent LeVien was appointed as Class II director at Celularity Inc.
“On June 5, 2025, the Board of Directors of Celularity Inc. (the “Company”) appointed Vincent LeVien as a Class II director of the Company to serve until the Annual Meeting of Stockholders to be held in 2026.”
Dean Kehler resigned as director at Celularity Inc.
“On May 14, 2025, Dean Kehler, a director of Celularity Inc. (the “Company”), resigned as a member of the Board of Directors of the Company.”
Celularity Inc received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 16, 2025, Nasdaq provided formal notice to Celularity that as a result of Celularity’s failure to timely file its 2024 Form 10-K, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively. Celularity is required to submit to Nasdaq a plan to regain compliance within 60 calendar days, or by June 16, 2025, and i”
Celularity Inc received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“November 21, 2024, the Company informed the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) that it failed to timely file its Q3 2024 Form 10-Q within the extension period provided by Rule 12b-25 because the Company had not yet completed the preparation of the financial statements. On November 21, 2024, Nasdaq provided formal notice to the Company that as a result of the Company’s failure to timely file its Q3 2024 10-Q, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). Nasdaq’s”
Adrian Kilcoyne resigned as Executive Vice President and Chief Medical Officer at Celularity Inc.
“Adrian Kilcoyne, M.D., M.P.H., M.B.A. of Celularity Inc., or Celularity, provided notice of resignation from his role as Executive Vice President and Chief Medical Officer, effective as of August 6, 2024, to pursue other opportunities.”
Richard J. Berman was appointed as Director at Celularity Inc.
“On August 27, 2024, the board of directors, or the Board, of Celularity Inc., or Celularity, appointed Richard J. Berman, as a Class II director to fill the vacancy left by the resignation of Robin L. Smith, M.D.”
Marc Mazur resigned as Director at Celularity Inc.
“On July 31, 2024, Marc Mazur, a Class III member of the Board of Directors of Celularity, notified the Board of Directors of his intention to resign as a member of the board and all committees thereof effective July 31, 2024.”
Celularity Inc received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 17, 2024, Celularity informed the Listing Qualifications department of the Nasdaq Stock Market LLC, or Nasdaq, that it failed to timely file its 2023 Form 10-K within the extension period provided by Rule 12b-25 because Celularity had not yet completed the preparation of the financial statements for the year ended December 31, 2023. On April 17, 2024, Nasdaq provided formal notice to Celularity that as a result of Celularity’s failure to timely file its 2023 Form 10-K, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listin”
Celularity Inc incurred convertible notes of $3.15 million convertible promissory note for $2.99 million in cash with YA II PN, LTD at annual rate equal to 8.0% (increased to 18.0% in the event of default) maturing March 13, 2025.
“Upon entry into the SEPA, Celularity issued Yorkville a $3.15 million convertible promissory note for $2.99 million in cash (after a 5% original issue discount), or the Initial Advance. The note bears interest at an annual rate equal to 8.0% (increased to 18.0% in the event of default as provided in the note), and matures March 13, 2025.”
Celularity Inc entered into RWI Forbearance Agreement with Resorts World Inc Pte Ltd (effective 2024-03-13).
“On March 13, 2024, Celularity and Resorts World Inc Pte Ltd, or RWI, entered into a forbearance agreement, or the RWI Forbearance Agreement, with respect to the Second Amended and Restated Loan Agreement”
Celularity Inc entered into Registration Rights Agreement with YA II PN, LTD (effective 2024-03-13).
“in connection with the entry into the SEPA, on March 13, 2024, Celularity entered into a registration rights agreement with Yorkville”
Celularity Inc entered into Standby Equity Purchase Agreement with YA II PN, LTD valued at up to $10.0 million (effective 2024-03-13).
“On March 13, 2024, Celularity Inc., or Celularity, entered into a Standby Equity Purchase Agreement, or the SEPA, with YA II PN, LTD, a Cayman Islands exempt limited partnership, or Yorkville.”
Celularity Inc: Approved and filed a certificate of amendment to effect a 1-for-10 reverse stock split of Class A common stock (effective 2024-02-28).
“Celularity filed a certificate of amendment to the Charter, or the Certificate of Amendment, with the Secretary of State of the State of Delaware on February 22, 2024, which will take effect at 5:00 p.m. (Eastern Time) on February 28, 2024, and following which each ten shares of Common Stock issued and outstanding immediately prior thereto will be automatically reclassified, combined, converted and changed into one share of Common Stock, or the Reverse Stock Split.”
Celularity Inc shareholders approved Stockholders approved the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for the above proposals.
“Stockholders approved the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for the above proposals. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 134,165,134 2,054,505 201,903 -”
Celularity Inc shareholders rejected Stockholders did not approve the issuance or potential issuance of shares of Common Stock issuable upon the exercise of Tranche 2 Warrants to purchase shares of Common Stock issued to Resorts World Inc Pte Ltd at the 2024-01-16 meeting.
“Stockholders did not approve the issuance or potential issuance of shares of Common Stock issuable upon the exercise of Tranche 2 Warrants to purchase shares of Common Stock issued to Resorts World Inc Pte Ltd, or RWI, on January 16, 2024, with an exercise price that may be equal to or less than $0.24898 per share, which was the “Minimum Price” pursuant to Nasdaq Rule 5635(d) on the date of agreement to issue the Tranche 2 Warrants. The proposal failed to receive the affirmative vote of the holders of a majority of the voting power of the stock of the shares present at the Special Meeting and entitled to vote thereon. Dragasac Limited, an affiliate of the parent company to RWI, abstained from voting on the matter. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 66,443,495 956,202 51,559,153 17,462,692”
Celularity Inc shareholders approved Stockholders approved an amendment to Celularity’s Charter to effect a reverse stock split of Celularity’s Common Stock at a ratio to be determined by Celularity’s Board within a range of 1-for-10 to 1-for-100.
“Stockholders approved an amendment to Celularity’s Charter to effect a reverse stock split of Celularity’s Common Stock at a ratio to be determined by Celularity’s Board within a range of 1-for-10 to 1-for-100 (or any number in between), to be effected in the sole discretion of the Board without further approval or authorization from Celularity’s stockholders The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 132,805,636 3,544,785 71,121 -”
Celularity Inc amended amended and restated distribution and manufacturing agreement with an affiliate of Dragasac.
“As a condition to closing, Celularity entered into an amendment to an amended and restated distribution and manufacturing agreement with an affiliate of Dragasac, to add cell therapy products in clinical development, investigational stage and/or in near-term commercial use to the list of products under the scope of the exclusive distribution and manufacturing licenses (including unmodified natural killer cells (such as CYNK-001) for aging and other non-oncology indications, PSC-100, PDA-001, PDA-002, pEXO and APPL-001 for regenerative indications).”
Celularity Inc entered into investor rights agreement with Dragasac Limited (effective 2024-01-12).
“In connection with the execution of the purchase agreement, Celularity and Dragasac Limited also entered into an investor rights agreement dated as of January 12, 2024.”
Celularity Inc entered into second amended and restated senior secured loan agreement with Resorts World Inc Pte Ltd valued at $15.0 million (effective 2024-01-12).
“On January 12, 2024, Celularity and Celularity LLC, a wholly owned subsidiary of Celularity, entered into a second amended and restated senior secured loan agreement, or the Second Amended Loan, with Resorts World Inc Pte Ltd, or RWI, to amend and restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended on June 20, 2023, in its entirety.”
Celularity Inc entered into securities purchase agreement with Dragasac Limited valued at approximately $6.00 million (effective 2024-01-12).
“On January 12, 2024, Celularity Inc., or Celularity, entered into a securities purchase agreement with an existing investor, Dragasac Limited, providing for the private placement of (i) 21,410,983 shares of its Class A common stock, par value $0.0001 per share, or the Class A common stock, and (ii) accompanying warrants to purchase up to 5,352,746 shares of Class A common stock, or the PIPE Warrants, for $0.24898 per share and $0.125 per accompanying PIPE Warrant, for an aggregate purchase price of approximately $6.00 million.”
Celularity Inc reported full year 2023 results: revenue expected net sales ... to be in the range of $22.06 million to $22.76 million. Guidance reaffirmed.
“Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include”
Celularity Inc reported fourth quarter 2023 results: revenue expected net sales ... to be in the range of $11.4 million to $12.1 million. Guidance reaffirmed.
“Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and”
Robin L. Smith, MD resigned as Class II member of the board of directors at Celularity Inc.
“On December 24, 2023, Robin L. Smith, MD, a Class II member of the board of directors of Celularity Inc., or Celularity, notified the board of directors of her intention to resign as a member of the board effective December 24, 2023.”
Celularity Inc entered into Letter Agreement to Extend Pre-Paid Advance Agreement with YA II PN, Ltd. valued at Amendment extending maturity date to 2023-12-31; partial paydown of $2,500,000; issuance of 2,707,30 (effective 2023-09-18).
“On September 18, 2023, Celularity Inc., or the Company, entered into a letter agreement with YA II PN, Ltd., or Yorkville, to extend the maturity date of the Pre-Paid Advance Agreement dated September 15, 2022, or PPA, from September 15, 2023 to December 31, 2023. Additionally, Yorkville agreed not to declare an event of default, as defined in the PPA, until January 1, 2024.”
Lim Kok Thay resigned as Class II member of the board of directors at Celularity Inc.
“On September 14, 2023, Lim Kok Thay, a Class II member of the board of directors of the Company, notified the board of his intention to resign as a member of the board and all committees thereof effective immediately.”
Geoffrey Shiu Fei Ling was appointed as Class I Director at Celularity Inc.
“the board appointed Geoffrey Shiu Fei Ling, M.D., as a Class I director to fill the vacancy left by the resignation of Dr. von Eschenbach, to serve until his successor is elected and qualified”
Andrew C. von Eschenbach resigned as Class I Director at Celularity Inc.
“Andrew C. von Eschenbach, M.D., a Class I member of the board of directors of Celularity Inc., or Celularity, notified the board of directors of his intention to resign as a member of the board and all committees thereof effective August 31, 2023.”
Celularity Inc incurred loan of $3.0 million with Dr. Robert Hariri and two unaffiliated lenders at 15% per year maturing August 21, 2024.
“On August 21, 2023, Celularity Inc., or Celularity, entered into a Loan Agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing for a loan in the aggregate principal amount of $3.0 million (of which Dr. Hariri contributed $1.0 million), or the Loan.”
Celularity Inc entered into Loan Agreement with Dr. Robert Hariri and two unaffiliated lenders valued at $3.0 million (effective 2023-08-21).
“On August 21, 2023, Celularity Inc., or Celularity, entered into a Loan Agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing for a loan in the aggregate principal amount of $3.0 million”
John Sculley resigned as Class III member of the board of directors at Celularity Inc.
“On July 31, 2023, John Sculley, a Class III member of the board of directors of Celularity Inc., or Celularity, notified the board of directors of his intention to resign as a member of the board and all committees thereof effective August 4, 2023.”
Celularity Inc amended Warrant Amendment with institutional accredited investor valued at reduced exercise price to $0.45 per share (effective 2023-07-27).
“In connection with the offering described above, Celularity also entered into an amendment to certain existing warrants to purchase up to an aggregate of 8,928,572 shares at an exercise price of $0.75 per share and a termination date of October 10, 2028 (consisting of all of the warrants originally issued in May 2022 and a portion of which were issued in April 2023), pursuant to which, effective upon the closing of the offering, such amended warrants will have a reduced exercise price of $0.45 per share.”
Celularity Inc entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7% cash fee plus $50,000 legal expenses (effective 2023-07-27).
“In connection with the Purchase Agreement, Celularity entered into a placement agency agreement, or Placement Agency Agreement, with A.G.P./Alliance Global Partners, or A.G.P., pursuant to which A.G.P. agreed to serve as exclusive placement agent for the issuance and sale of the shares of Class A common stock and accompanying warrants.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.